BRIEF-Denali Therapeutics Announces Key Anticipated Milestones And Priorities For 2026
Reuters
Jan 06
BRIEF-Denali Therapeutics Announces Key Anticipated Milestones And Priorities For 2026
Jan 6 (Reuters) - Denali Therapeutics Inc DNLI.O:
DENALI THERAPEUTICS ANNOUNCES KEY ANTICIPATED MILESTONES AND PRIORITIES FOR 2026 INCLUDING COMMERCIAL LAUNCH OF TIVIDENOFUSP ALFA FOR HUNTER SYNDROME
DENALI THERAPEUTICS INC - FDA LIFTS CLINICAL HOLD ON DNL952, PHASE 1 STUDY TO PROCEED
DENALI THERAPEUTICS INC - PREPARES FOR FDA APPROVAL AND LAUNCH OF TIVIDENOFUSP ALFA
Source text: ID:nGNX5hmFVt
Further company coverage: DNLI.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.